ClinicalTrials.gg
Active, not recruitingNCT05972473Updated Mar 13, 2025

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

A Phase 3 interventional study of Aflibercept Ophthalmic and IBI302 in Neovascular Age-related Macular Degeneration, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
4th of 91
600 · median 62
Started
2023
with 13 others
Phase 3
18 of 106
4 open now
Primary completion
2027-02
later than 26 of 42 live
Registered
68th of 106
by date
Lead sponsor
7 of 106
Innovent Biologics (Suzhou) Co. Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 4th largest by enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 3, reaches primary completion later than 26 of the 42 other live ones, and was the 68th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to study participation;
  2. Male or female ≥ 50 years of age at the time of signing the informed consent;
  3. Active subfoveal CNV secondary to nAMD, or active CNV with intra/subretinal fluid involving the fovea;
  4. BCVA of 19 to 78 ETDRS letters (inclusive) in the study eye at baseline.

Exclusion criteria

Exclusion Criteria:

  1. Ocular disease:

    • Any concurrent intraocular condition/systemic disease in the study eye at screening or baseline that, in the judgment of the investigator, may cause the participant fail to respond to the treatment or confuse the interpretation of study results;
    • Total lesion area(including blood, atrophy, fibrosis, PED and neovascularization)> 12 optic disc area (DA) on FFA;
    • Subretinal hemorrhage area > 50% of the total lesion area, or subretinal hemorrhage area involving macular fovea ≥ 1 DA;
    • Fibrosis or atrophy area > 50% of the total lesion area, or involving the fovea; Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg after standard treatment);
    • Presence of active intraocular or periocular infection or inflammation;
  2. Ocular treatment:

    • Anti-VEGF or anti-complement therapy in the study eye within 90 days prior to baseline;
    • Fundus laser photo-coagulation in the study eye within 90 days prior to baseline;
    • Photodynamic Therapy (PDT) in the study eye within 90 days prior to baseline;
    • History of vitreoretinal surgery, penetrating keratoplasty in the study eye;
  3. General condition or treatment:

    • Uncontrolled hypertension (defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg after standard treatment);
    • > 8% within 28 days prior to baseline; Systemic anti-VEGF drug and anti-complement drug therapy within 90 days prior to baseline;
    • History of to any component of the test article, control article, or sensitivity to fluorescein dye, povidone-iodine;
    • Pregnant or lactating women; Inappropriate for the study (e.g., substance abuse, inability or unwillingness to follow the trial protocol), as judged by the investig.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Active comparator
    Aflibercept

    Drug: Aflibercept 2mg/eye; Intraocular injection

    Drug: Aflibercept Ophthalmic

  • Experimental
    IBI302 dose 8mg

    Drug: IBI302 8mg/eye; Intraocular injection

    Biological: IBI302

Interventions

  • 2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).

  • BiologicalIBI302

    8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in Best corrected visual acuity ( BCVA ) in the study eye.

    Change from Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at week 44, 48, 52.

    Time frame: At week 44, 48, 52

Secondary outcomes

  1. The proportion of participants with absence intraretinal fluid (IRF) and absence subretinal fluid (SRF) in the fovea at Week 16

    The intraretinal fluid and subretinal fluid is measured by optical coherence tomography (OCT) in the central subfield(center 1 millimeter)

    Time frame: At week 16

  2. Change from baseline in BCVA at Week 52 and 100

    Best corrected visual acuity (BCVA) was measured on early treatment diabetic retinopathy study(ETDRS) chart at a starting distance of 4 meters. The BCVAletter score ranges from 0 to 100(best score), and a gain in BCVA from baseline indicates an improvement in visual acuity.

    Time frame: Upto Week 100

  3. Change from baseline in central subfield thickness (CST) measured by optical coherence tomography (OCT) at Week 52 and 100

    Central subfield thickness was defined as the distance between the internal limiting member and the Bruch's member using OCT, as assessed by the central reading center.

    Time frame: Upto Week 100

  4. Change from baseline in area of CNV on fundus fluorescence angiography (FFA) at Week 52 and 100

    the area of the choroidal neovascularization lesion in the study eye was measured by a central reading center using FFA

    Time frame: Upto Week 100

  5. Proportion of participants on a q8W, q12W, and q16W treatment intervals at Week 52 and 100

    Percentages are based on number of participants randomized to the IBI302 group who have not discontinued the study at week 52 and 100. the treatment interval at a givven visit is defined as the treatment interval decision followed at that visit.

    Time frame: Upto Week 100

  6. Incidence, relatedness to the study drug and severity of ocular and Non-ocular adverse events (AE), treatment emergent adverse events (TEAE) and serious adverse events (SAE).

    All AEs were recorded and the investigator made an assessment of seriousness,severity, and causality of each AE.

    Time frame: Upto Week 100

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 41 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 2, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05972473
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Sep 21, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion